Market capitalization | €12.97m |
Enterprise Value | €2.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.37 |
P/S ratio (TTM) P/S ratio | 1.74 |
P/B ratio (TTM) P/B ratio | 1.32 |
Revenue growth (TTM) Revenue growth | -17.51% |
Revenue (TTM) Revenue | €7.45m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast MediGene AG:
1 Analyst has issued a forecast MediGene AG:
Jun '24 |
+/-
%
|
||
Revenue | 7.45 7.45 |
17%
17%
|
|
Gross Profit | 4.77 4.77 |
134%
134%
|
|
EBITDA | -14 -14 |
53%
53%
|
EBIT (Operating Income) EBIT | -16 -16 |
49%
49%
|
Net Profit | -16 -16 |
45%
45%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.
Head office | Germany |
CEO | Selwyn Ho |
Employees | 86 |
Founded | 1994 |
Website | www.medigene.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.